Indaptus Therapeutics Inc is trading 5.6% up at $4.75 in pre-market, extending a sharp multi-day rally following significant gains on June 10–11 and June 17.
- The move appears to be momentum-driven follow-through within a strong broader market backdrop, as no fresh company-specific news, SEC filings, or analyst calls have been reported for June 18.
- There are currently no new FDA or clinical updates to account for the continued upward price action.